May 29, 2018
Authored and Edited by Thomas L. Irving; Leon Lin*
On May 9, 2018, FDA issued draft guidance on Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the FDCA. Section 582 requires trading partners (defined in Section 581(23) of the FDCA) in the pharmaceutical distribution supply chain, with the exception of third-party logistic providers, to comply with certain traceability requirements. The draft guidance provides recommendations for how trading partners and stakeholders should request an exemption from FDA under Section 582. The draft guidance also describes the process for both FDA-initiated Exceptions and Exemptions, as well as FDA review and renewal of waivers, exceptions, and exemptions.
A party seeking a waiver, exception, or exemption from the requirements of 582 should submit a written request to the FDA according to the guidelines established in the draft guidance. All trading partners required to follow Section 582 may request a waiver under section 582(a)(3)(A)(i), but only a manufacture or repackager may request an exemption under 583(A)(3)(A)(ii) and any interested stakeholder may request an exemption under 582(A)(3)(A)(iii). The FDA itself may also initiate exceptions and exemptions under 582(a)(3)(A)(ii) and 582(a)(3)(A)(iii).
Upon the FDA’s determination that the request lacks sufficient information to permit a substantive review, the Agency may deny the request or contact a requesting trade partner or stakeholder to clarify an aspect of the request. If a review is permitted, the FDA intends to determine whether:
Requesting parties will be notified in writing by the FDA of its determination and explanation to grant, deny, or take other appropriate action on the request. If the FDA grants a request that the Agency itself initiated, FDA will communicate the information in writing using an appropriate method for the parties affected. If a request is granted, the recipient is responsible for notifying the FDA within a reasonable amount of time if there is a material change in the circumstances that were the basis for granting the initial request for relief.
The Agency intends to review the granted requests every 2 years and renew such requests as applicable. Recipients of granted requests may submit a renewal request to the FDA Center that originally issued the waiver. The FDA does not intend to accept a renewal request for an FDA-initiated exception or exemption.
Readers are encouraged to read the draft guidance, also available on the FDA's website.
*Leon Lin is a Law Clerk at Finnegan
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.